The incidences of heart diseases have registered an uptick in the recent past. Moreover, increased life expectancy has burgeoned the geriatric population pool, thus augmenting demand for heart valve devices.
Based on these trends, the demand for minimally invasive procedures, such as transcatheter aortic valve replacement (TAVI) procedures, have increased. This has led to an overall improvement in the quality of lives for heart patients. Manufacturers are further motivated to invest in newer avenues of heart valve devices.
For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4759
On the back of these factors, the global heart valve devices market is anticipated to grow staggeringly, at a healthy CAGR of 13.4% during the forecast period (2020-2025). The global heart valve devices market shall surpass a valuation of US$ 16.2 Bn by the end of 2025.
Key Takeaways of Global Heart Valve Devices Market Study:
- By type, transcatheter heart valves segment demonstrates promising growth. New product launches and increasing demand for minimally invasive procedures are anticipated to leverage the segment’s growth. More than 40% of the global heart valve devices market shall be held by transcatheter valves.
- Biological heart valves shall surge in popularity, attributed to increased usage among adults below the age of 60. Moreover, biological valves prevent blood clotting, thus eradicating the need to take anti-coagulant medications. The segment shall capture nearly one-third of the global heart valve devices market.
- By end-use, hospitals shall dominate the global heart valve devices market, comprising more than 70% of the overall market share. Growth of this segment can be attributed to patients’ first choice of place for surgery. In addition, hospitals also provide effective post-surgical care and monitoring.
- North America shall remain in the forefront of growth in the global heart devices market, accounting for more than two-fifths of the overall market share. Increasing FDA approvals of technologically advanced transcatheter aortic valves has expanded revenues of key players, thus augmenting market growth. Anticipated CAGR for this region is 13.7% throughout the forecast period.
- Asia-Pacific shows healthy growth prospects, motivated by increased investment in heart devices by key manufactures and improved healthcare infrastructure. Majority of the growth is driven by mechanical heart devices due to their affordability and increased lifespan of patients. The region is set to expand at a CAGR of 14.4% during the forecast period.
For critical insights on this market, request for methodology here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4759
“Minimally invasive surgical procedures, such as transcatheter aortic valve replacement (TAVR), are gaining significant traction since the past few years. Increasing demand for such procedures is stimulating key manufacturers to launch appropriate devices, thus proliferating the demand for heart valve devices,” concludes a Fact.MR analyst.
New Product Ventures a Forte of Key Market Players:
The global heart valve devices is consolidated, with three key players, Edward Scientific Corporation, Medtronic and Abbott Laboratories comprising more than half of the total market. Other players such as Boston Scientific Corporation, CryoLife Inc. and JenaValve Technology, Inc. also have considerable market presence.
Out of these, Edward Scientific Corporation is the leader in the global heart valve devices market. Through a three-pronged approach which is based on patient focused care, addressing unmet structural heart disease patient needs and innovation; the company expands its operations. Some of the products manufactured by Edward Scientific include the SAPIEN Transcatheter Heart Valve and the Magna Ease Aortic/Mitral Valve.
For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4759
Likewise, Abbott Laboratories product pipeline in the cardiovascular business segment consists of transcatheter aortic heart valve system, left arterial appendage occlude and pacemakers, among others. Its structural heart products segment include the MitraClip Transcatheter Mitral Valve Repair.
Read More Trending and Similar Reports from Fact.MR – https://www.globenewswire.com/en/news-release/2019/02/27/1743437/0/en/CHG-Accounts-for-Nearly-60-Share-of-Antiseptic-Bathing-Products-Market-Fact-MR-Study.html
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com
